normal level Vitamin D — Competitive Intelligence Brief

normal level Vitamin D (normal level Vitamin D) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog. Area: Osteoporosis.

phase 3 Vitamin D analog Vitamin D receptor Osteoporosis Small molecule

Target snapshot

normal level Vitamin D (normal level Vitamin D) — National Cancer Institute, Naples. Vitamin D is essential for maintaining normal levels of calcium and phosphate in the body, which is crucial for bone health.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
normal level Vitamin D TARGET	normal level Vitamin D	National Cancer Institute, Naples	phase 3	Vitamin D analog	Vitamin D receptor
Cholecalciferol 12 000 UI	Cholecalciferol 12 000 UI	Assistance Publique - Hôpitaux de Paris	marketed	Vitamin D supplement	Vitamin D receptor (VDR)
ibandronate, calcium and vitamin D	ibandronate, calcium and vitamin D	Charite University, Berlin, Germany	marketed	Bisphosphonate combination therapy	Farnesyl pyrophosphate synthase (ibandronate); calcium-sensing receptor and vitamin D receptor (supportive agents)
cholecalciferol (vitamin D3)	cholecalciferol (vitamin D3)	Medical University of South Carolina	marketed	Vitamin D analog / Secosteroid	Vitamin D receptor (VDR)
calcipotriol hydrate [Daivonex]	calcipotriol hydrate [Daivonex]	Hoffmann-La Roche	marketed	Vitamin D3 analog	Vitamin D receptor (VDR)
Ibandronate+alfacalcidol+calcium	Ibandronate+alfacalcidol+calcium	Chinese University of Hong Kong	marketed	Bisphosphonate + active vitamin D + mineral supplement combination	Farnesyl pyrophosphate synthase (ibandronate); vitamin D receptor (alfacalcidol); calcium channels (calcium)
Calcifediol Oral Product	Calcifediol Oral Product	OPKO Health, Inc.	marketed	Vitamin D analog	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D analog class)

1. LEO Pharma · 2 drugs in this class
2. Genzyme, a Sanofi Company · 2 drugs in this class
3. National Cancer Institute, Naples · 2 drugs in this class
4. OPKO Health, Inc. · 2 drugs in this class
5. Joslin Diabetes Center · 1 drug in this class
6. Kyowa Kirin, Inc. · 1 drug in this class
7. Maimónides Biomedical Research Institute of Córdoba · 1 drug in this class
8. Shanghai Jiao Tong University Affiliated Sixth People's Hospital · 1 drug in this class
9. Shiraz University of Medical Sciences · 1 drug in this class
10. St. Justine's Hospital · 1 drug in this class